NASDAQ:GLMD

Galmed Pharmaceuticals - GLMD News Today

$0.45

+0.02 (+4.65%)

(As of 03/29/2023 12:00 AM ET)

Add

Compare

Today's Range: $0.37
▼
$0.45
50-Day Range: $0.40
▼
$0.75
52-Week Range: $0.29
▼
$1.84

Volume: 118,932 shs
Average Volume: 27,684 shs
Market Capitalization: $11.29 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Institutional Ownership

Get Galmed Pharmaceuticals News Delivered to You Automatically

GLMD Media Mentions By Week

GLMD Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

GLMD
News Sentiment
▼
0.22

0.61
▲
Average
Medical
News Sentiment

GLMD News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

GLMD Articles
This Week
▼
4

0
▲
GLMD Articles
Average Week

Source

Source	Headline
	Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022 finance.yahoo.com - March 29 at 7:35 PM
	Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Given Consensus Rating of "Hold" by Brokerages americanbankingnews.com - March 26 at 5:08 AM
	Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by StockNews.com americanbankingnews.com - March 22 at 4:26 AM
	GLMD Galmed Pharmaceuticals Ltd. seekingalpha.com - February 17 at 8:12 AM
	Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt finance.yahoo.com - February 8 at 10:28 AM
	Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth? finance.yahoo.com - January 6 at 8:30 AM
	Galmed Pharmaceuticals Shares Up 9.2% on Data From Liver Treatment Aramchol Study marketwatch.com - January 4 at 5:42 PM
	Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol finance.yahoo.com - January 4 at 12:41 PM
	Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement finance.yahoo.com - December 14 at 7:01 PM
	Galmed Pharmaceuticals (GLMD) Moves to Buy: Rationale Behind the Upgrade finance.yahoo.com - September 14 at 3:16 PM
	Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results finance.yahoo.com - August 4 at 1:02 PM
	Galmed's Aramchol Shows Anti-Fibrotic Effects In Lung Fibrosis Animal Model finance.yahoo.com - July 7 at 4:15 PM
	Galmed: New Data Reinforces Expansion Of Aramchol's Clinical Development To Additional Indications nasdaq.com - July 7 at 9:46 AM
	Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model finance.yahoo.com - July 7 at 9:46 AM
	Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification finance.yahoo.com - June 17 at 7:16 PM
	Galmed Pharmaceuticals (NASDAQ:GLMD), Analyst Ratings, Price Targets, Predictions benzinga.com - May 25 at 8:49 AM
	Galmed Pharmaceuticals shares fall after downgrade by Raymond James analyst seekingalpha.com - May 18 at 6:52 PM
	Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects finance.yahoo.com - May 17 at 11:50 AM
	Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results finance.yahoo.com - May 17 at 11:50 AM
	Galmed Pharmaceuticals Shares Down 16% marketwatch.com - May 3 at 3:52 PM
	Raymond James Maintains Outperform Rating for Galmed Pharmaceuticals: Here's What You Need To Know markets.businessinsider.com - May 3 at 3:52 PM
	Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2021 Results - Earnings Call Transcript seekingalpha.com - May 2 at 6:15 PM
	Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results finance.yahoo.com - May 2 at 8:14 AM
	Galmed Pharmaceuticals's Earnings Outlook benzinga.com - April 29 at 8:45 PM
	Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment finance.yahoo.com - April 28 at 8:07 AM
	Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2 finance.yahoo.com - April 26 at 12:05 PM
	Galmed gains 5% after securing three new U.S. patents for Aramchol and meglumine salt seekingalpha.com - January 11 at 9:01 AM
	Galmed Pharmaceuticals Ltd Shares Fall 5.2% Below Previous 52-Week Low - Market Mover nasdaq.com - January 11 at 9:01 AM
	Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt finance.yahoo.com - January 11 at 9:01 AM
	Galmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study finance.yahoo.com - January 10 at 5:42 PM
	Here's Why We're Watching Galmed Pharmaceuticals' (NASDAQ:GLMD) Cash Burn Situation nasdaq.com - November 11 at 10:06 AM
	Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement finance.yahoo.com - November 8 at 9:54 AM
	Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results finance.yahoo.com - November 8 at 9:54 AM
	Galmed Reveals Early Aramchol Data From Late-Stage NASH Trial finance.yahoo.com - November 1 at 6:38 PM
	Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study finance.yahoo.com - November 1 at 1:37 PM
	Galmed Pharmaceuticals Ltd. (GLMD) finance.yahoo.com - October 26 at 1:31 AM
	Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature Medicine finance.yahoo.com - October 11 at 9:13 AM
	Trillium (TRIL) to be Acquired by Pfizer for $2.3 Billion finance.yahoo.com - August 24 at 5:57 PM
	Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action finance.yahoo.com - August 19 at 5:08 PM
	Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specific anti-inflammatory compound finance.yahoo.com - August 19 at 12:08 PM
	MHRA Agrees with Galmed's Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study finance.yahoo.com - August 16 at 8:48 AM
	Catalyst (CPRX) Up More Than 20% in Past 3 Months: Here's Why finance.yahoo.com - August 12 at 11:32 AM
	Thinking about buying stock in Autoweb, Processa Pharmaceuticals, Harmonic, Galmed Pharmaceuticals, or Sigma Labs? benzinga.com - August 5 at 6:13 PM
	Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results finance.yahoo.com - August 5 at 8:12 AM
	Galmed Pharma jumps 8% on FDA green light to use Aramchol Meglumine in late-stage ARMOR study seekingalpha.com - August 4 at 9:49 AM
	We Think Galmed Pharmaceuticals (NASDAQ:GLMD) Needs To Drive Business Growth Carefully finance.yahoo.com - August 3 at 1:40 PM
	Galmed Stock Jumps As FDA Signs Off Use Of Aramchol Meglumine In Late Stage NASH Trial finance.yahoo.com - August 2 at 2:12 PM
	FDA Agrees With Galmed' Plan To Use Aramchol Meglumine In Phase 3 Study; Stock Up nasdaq.com - August 2 at 9:11 AM
	Galmed Pharmaceuticals to Report Second Quarter 2021 Financial Results and Provide Business Update on Thursday August 5 finance.yahoo.com - July 29 at 9:20 AM
	Galmed Pharmaceuticals Ltd. Ordinary Shares (GLMD) nasdaq.com - June 7 at 6:28 PM

Get Galmed Pharmaceuticals News Delivered to You Automatically

This page (NASDAQ:GLMD) was last updated on 3/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Galmed Pharmaceuticals - GLMD News Today

GLMD Media Mentions By Week

GLMD Media Sentiment

GLMD News Coverage

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info